Antiretroviral Management Charts and Tables

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Special Situations

		Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis Ian R. McNicholl, PharmD, BCPS, and Rudolph A. Rodriguez, MD, University of California San Francisco. Updated October 2012.

		Dosing for Ritonavir-Boosted Protease Inhibitors Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated July 2010.

Adverse Effects

		Adverse Effects of Antiretroviral Drugs Ian McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.

		Adverse Events Due to Nonantiretroviral Medications during Treatment of HIV-Related Infections and Complications Ian McNicholl, PharmD, BCPS, and Christine Jamjian, PharmD, University of California San Francisco. Updated October 2012.

		Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects Table 13, Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. March 27, 2012.

Drug Characteristics

		Antiretroviral Drug Profiles Susa Coffey, MD, and Laurence Peiperl, MD. University of California San Francisco.

		Currently Approved Drugs for HIV: A Comparative Chart AIDSmeds.com. Table showing standard antiretroviral dosages, plus dosing and side effect considerations and links to in-depth drug monographs.

Drug Interactions

		ARV Interactions with HCV Serine Protease Inhibitors Susa Coffey, MD, and Annie Luetkemeyer, MD, University of California San Francisco. Updated January 2013.

		Database of Antiretroviral Drug Interactions HIV InSIte, Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Create custom reports with this interactive tool.

		Dosage Adjustments for ARV-ARV Drug Interactions Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.

		Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonists Table 14, Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. March 27, 2012.

		Etravirine-ARV Interactions Susa Coffey, MD, HIV InSite Medical Editor; Ian R. McNicholl, PharmD, HIV InSite Pharmacy Editor. Updated July 2011. Reference table to help clinicians navigate the complexities of drug interactions with this NNRTI.

		Interactions between ARVs and Statin Medications: Recommendations for Coadministration Susa Coffey, MD, HIV InSite Medical Editor. Updated October 2012.

		Recreational Drugs and HIV Antivirals: A Guide to Interactions for Clinicians Christine Kubin, PharmD, and Antonio Urbina, MD, New York/New Jersey AIDS Education and Training Center. 2008. Contains information on interactions with alcohol, street drugs, and erectile dysfunction agents.

Regimen Selection / Treatment Strategy

Summary tables from the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Panel on Antiretroviral Guidelines for Adult and Adolescents. U.S. Department of Health and Human Services. March 27, 2012.


	Preferred and Alternative Antiretroviral Regimens for Antiretroviral Therapy-Naive Patients (Table 5a)


	Acceptable Antiretroviral Regimens for Treatment-Naive Patients (Table 5b)


	Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (Table 6)


	ARV Regimens or Components Not Recommended as Initial Therapy (Table 7)


	ARV Regimens or Components That Should Not Be Offered at Any Time (Table 8)

Access Information

		FDA-Approved and Investigational Antiretrovirals HIV InSite. Comprehensive chart of FDA-approved and experimental drugs.

		Expanded Access, Compassionate Use, and Treatment IND Programs HIV InSite. Listing of programs that provide patients with limited access to promising experimental treatments before the medications have been given full approval by the U.S. Food and Drug Administration. November 2007.

		Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan (PEPFAR) U.S. Food and Drug Administration. Table detailing FDA approvals as part of a special initative for granting approval to manufacturers of generic antiretrovirals so that these drugs may be purchased for use outside the U.S. and paid for with PEPFAR funding.

Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco